# 2025年12月10日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 成人重症医学医师核心知识与技能的确定：一项多学科修订德尔菲法研究结果

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41363909)
**期刊：** Critical care medicine
**PMID：** 41363909
**DOI：** 10.1097/CCM.0000000000006978

### 第一部分 原文与翻译

**英文原标题：** Determination of Adult Critical Care Physician Core Knowledge and Skills: Results of a Multidisciplinary, Modified Delphi Process.

> **英文摘要：**
> OBJECTIVES: In the United States, training for physicians who manage critically ill adult patients (intensivists) evolved through parallel subspecialty critical care medicine (CCM) pathways with significant commonality. The Society of Critical Care Medicine Adult Critical Care Physician Core Knowledge and Skills Task Force aimed to delineate the common core knowledge and skills required of all intensivists.
> 
> DESIGN: A master list of content areas and procedural skills was compiled from all CCM subspecialty program requirements and blueprints of the certification examinations. Using a modified Delphi approach, participants were asked to categorize the knowledge items as "advanced knowledge is essential," "general, but not advanced, knowledge is essential," or "knowledge is not essential." Procedures were categorized as "intensivist performs routinely," "intensivist only performs in an emergency," or "intensivist knows" about the procedure.
> 
> SETTING: Representatives from CCM stakeholder organizations, including accreditation and certification organizations, critical care societies, and program directors' societies, were invited to participate.
> 
> SUBJECTS: Members of the Adult Critical Care Physician Core Knowledge and Skills Task Force of the Society of Critical Care Medicine.
> 
> INTERVENTIONS: For the first two rounds of the modified Delphi process, Research Electronic Data Capture was used. For the third and fourth rounds, the process was completed through online meetings with Zoom (Zoom Video Corporations, San Jose, CA) utilizing Zoom's polling feature.
> 
> MEASUREMENTS AND MAIN RESULTS: A total of 541 items were determined to be essential, with 145 requiring advanced knowledge and 323 requiring general knowledge. For 73 items, consensus regarding advanced vs. general could not be achieved, but they remained essential. Only eight items were felt to be nonessential. Of the 16 procedures, most were categorized as "intensivist performs."
> 
> CONCLUSIONS: The large number of items included in the list of essential knowledge and skills demonstrates the complexity of modern CCM. Utilization of a common framework across the subspecialties of CCM could lead to greater harmonization among the fellowship program requirements and certification examinations.

> **中文摘要：**
> 研究目的：在美国，负责照护重症成人患者的医师（重症医学专家）的培训通过平行的亚专科重症医学（CCM）路径逐步发展，并具有显著的共通性。重症医学学会成人重症医学医师核心知识与技能工作组旨在阐明所有重症医学医师应具备的共同核心知识与技能。
> 
> 研究设计：根据所有重症医学亚专科项目的要求及认证考试的蓝图，编制了内容领域和操作技能的主清单。采用修订的德尔菲法，请参与者将知识条目分为“必须具备的高级知识”、“必须具备的一般（但非高级）知识”或“非必需知识”。操作则根据重症医学医师的执行程度分为“常规执行”、“仅在紧急情况下执行”或“了解该操作”。
> 
> 研究场景：邀请了来自重症医学利益相关组织的代表参与，包括认证与资质组织、重症医学学会及项目主任协会。
> 
> 研究对象：重症医学学会成人重症医学医师核心知识与技能工作组成员。
> 
> 干预措施：在修订德尔菲法的前两轮中，采用研究电子数据采集系统（REDCap）。第三轮和第四轮通过在线会议（使用 Zoom 视频会议平台，美国加利福尼亚州圣何塞市）进行，并利用其投票功能完成。
> 
> 测量与主要结果：共确认541项内容为核心必需，其中145项需具备高级知识，323项需具备一般知识。有73项未能在“高级”与“一般”分类上达成共识，但仍被列为必需；仅8项被认为非必需。在16项操作中，大多数被归类为“重症医学医师常规执行”。
> 
> 结论：大量被列为核心必需的知识与技能条目显示出现代重症医学的复杂性。在各重症医学亚专科间采用统一框架，可能促进培训项目要求与认证考试的更好协调与一致。

### 第二部分 AI 大师评价

该研究通过多学科修订德尔菲法系统地界定了成人重症医学医师的核心知识与技能，旨在为培训和认证建立统一标准。研究方法学严谨，涵盖全国主要重症医学相关组织，结果确认了541个关键条目，体现了该领域知识体系的复杂与广泛。其创新之处在于构建了跨亚专科通用的知识框架，可促进教育与考核标准的协调。局限在于专家共识方法固有的主观性及其在国际适用性方面的局限。

---

## 2. 自动闭环通气与程序化常规通气对危重成人呼吸机无辅助天数的影响：一项随机临床试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41361939)
**期刊：** JAMA
**PMID：** 41361939
**DOI：** 10.1001/jama.2025.24384

### 第一部分 原文与翻译

**英文原标题：** Effect of Automated Closed-Loop Ventilation vs Protocolized Conventional Ventilation on Ventilator-Free Days in Critically Ill Adults: A Randomized Clinical Trial.

> **英文摘要：**
> IMPORTANCE: Automated closed-loop ventilation systems continuously adjust ventilator settings based on real-time physiologic feedback and may optimize lung-protective ventilation. Their effect on patient-centered outcomes in critically ill patients receiving ventilation remains uncertain.
> 
> OBJECTIVE: To determine whether early initiation of automated closed-loop ventilation increases ventilator-free days at day 28 compared with protocolized conventional ventilation.
> 
> DESIGN, SETTING, AND PARTICIPANTS: International, multicenter, randomized clinical trial conducted at 7 intensive care units (ICUs) in the Netherlands and Switzerland. Adult patients with less than 1 hour elapsed after initiation of invasive ventilation and expected to require ventilation for 24 hours or longer were enrolled between October 2020 and June 2025, with final follow-up completed at 90 days.
> 
> INTERVENTIONS: Patients were randomly assigned (1:1) to receive automated closed-loop ventilation using INTELLiVENT adaptive support ventilation (n = 602) or protocolized conventional ventilation (n = 599). Both groups followed standardized ventilation management, sedation, and weaning protocols.
> 
> MAIN OUTCOMES AND MEASURES: The primary outcome was the number of ventilator-free days at day 28, defined as days alive and free from invasive ventilation. Secondary outcomes included mortality, duration of ventilation among survivors, ICU and hospital lengths of stay, and ventilation quality. Safety outcomes included severe hypoxemia, hypercapnia, and need for rescue therapies, including prone positioning, recruitment maneuvers, or bronchoscopy.
> 
> RESULTS: Among 1514 randomized patients, 1201 (79%) were included in the modified intention-to-treat analysis (36% women; median age, 63 years). The median of ventilator-free days at day 28 was 16.7 days (IQR, 0.0-26.1 days) in the closed-loop ventilation group and 16.3 days (IQR, 0.0-26.5 days) in the conventional ventilation group (odds ratio, 0.91; 95% CI, 0.77-1.06; P = .23). There were no differences between groups in components of the primary outcome, ie, duration of ventilation in survivors and 28-day mortality. There were no differences in secondary outcomes except for ventilation quality, which was higher with closed-loop ventilation. Severe hypercapnia and hypoxemia were less frequent in the closed-loop group, and fewer patients required rescue therapies, primarily prone positioning, compared with the conventional group (non-statistically significant after multiplicity adjustment).
> 
> CONCLUSIONS AND RELEVANCE: Among critically ill adults receiving invasive mechanical ventilation, early use of an automated closed-loop ventilation system did not increase ventilator-free days at day 28 compared with protocolized conventional ventilation.
> 
> TRIAL REGISTRATION: Clinicaltrials.gov Identifier: NCT04593810.

> **中文摘要：**
> 重要性：自动闭环通气系统基于实时生理反馈持续调整呼吸机设定，可能优化肺保护性通气。然而，其在接受机械通气的危重患者中对以患者为中心的结局的影响尚不确定。
> 
> 目的：确定早期启动自动闭环通气相比程序化常规通气是否可增加第28天的呼吸机无辅助天数。
> 
> 设计、研究场所与参与者：这是一项在荷兰和瑞士7个重症监护病房（ICU）开展的国际多中心随机临床试验。入组对象为启动有创通气后不足1小时、预计需通气24小时以上的成年患者，入组时间为2020年10月至2025年6月，随访最终在90天完成。
> 
> 干预措施：患者按1:1比例随机分配，接受基于 INTELLiVENT 自适应支持通气的自动闭环通气（n=602）或程序化常规通气（n=599）。两组均遵循标准化的通气管理、镇静及撤机方案。
> 
> 主要结局与测量指标：主要结局为第28天呼吸机无辅助天数，即生存且无有创机械通气的天数。次要结局包括死亡率、生存者的通气持续时间、ICU及住院时间和通气质量。安全性结局包括重度低氧血症、高碳酸血症，以及需要救援治疗（如俯卧位、肺复张手法或支气管镜操作）的情况。
> 
> 结果：在1514名随机分配的患者中，1201名（79%）纳入修正意向性治疗分析（女性占36%，中位年龄63岁）。第28天呼吸机无辅助天数中位数在闭环通气组为16.7天（四分位距0.0–26.1天），在常规通气组为16.3天（四分位距0.0–26.5天）（比值比0.91；95%置信区间0.77–1.06；P=0.23）。两组在主要结局组成部分（如生存者通气持续时间和28天死亡率）方面无显著差异。除通气质量外，其余次要结局也无差异，而闭环通气组的通气质量更高。闭环组严重高碳酸血症和低氧血症的发生率较低，且需救援治疗（主要为俯卧位）的患者较少，但在多重比较调整后差异无统计学意义。
> 
> 结论与意义：在接受有创机械通气的危重成人中，早期使用自动闭环通气系统并未较程序化常规通气增加第28天的呼吸机无辅助天数。
> 
> 试验注册：Clinicaltrials.gov编号 NCT04593810。

### 第二部分 AI 大师评价

本研究是一项在荷兰和瑞士多中心开展的随机对照临床试验，旨在评估自动闭环通气相较程序化常规通气对危重成人通气结局的影响。试验结果显示，两种方式在第28天呼吸机无辅助天数、死亡率和住院时间等主要及多数次要结局上无显著差异，仅闭环组通气质量更优。尽管安全事件略少，但经多重比较调整后未达统计学显著。该研究为自动闭环通气在危重症机械通气中的临床价值提供了高质量证据，提示其在改善患者中心结局方面仍需进一步优化与验证。

---

## 3. 用于改善机械通气结局的自动化模式——机器中的幽灵

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41361933)
**期刊：** JAMA
**PMID：** 41361933
**DOI：** 10.1001/jama.2025.24401

### 第一部分 原文与翻译

**英文原标题：** Automated Modes to Improve Mechanical Ventilation Outcomes-The Ghost in the Machine.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

该论文标题暗示作者探讨了通过自动化通气模式改善呼吸机治疗效果的潜力，以及背后复杂的人机交互问题。虽然未提供摘要，但主题可能涉及人工智能与机械通气技术的结合。研究可能强调自动控制系统在重症监护中优化患者预后方面的前景，同时指出算法对临床决策透明度和信任的影响。整体而言，该文或具有前瞻性的技术讨论价值，但受限于缺乏具体研究数据。

---

## 4. 重症监护中有创呼吸机排气的气溶胶传播风险及管理策略——叙述性综述

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41361786)
**期刊：** Critical care (London, England)
**PMID：** 41361786
**DOI：** 10.1186/s13054-025-05787-9

### 第一部分 原文与翻译

**英文原标题：** Invasive ventilator exhaust in critical care: aerosol transmission risks and management strategies-a narrative review.

> **英文摘要：**
> Invasive mechanical ventilation (IMV) is essential in intensive care, yet aerosols released with ventilator exhaust remain an under-recognized source of airborne transmission and occupational exposure. This review outlines how exhaust-borne aerosols are generated and dispersed in clinical workflows, with amplification during airway suctioning, therapeutic nebulization, and inhaled volatile sedation. We compare principal mitigation options-including heat-and-moisture exchanger (HME) devices and high-efficiency particulate air filtration (HEPA), directed discharge, and chemical inactivation-across effectiveness, operational complexity, adaptability, and strength of evidence. Building on a patient-device-environment framework, we propose a scenario-based, three-tier prevention strategy that aligns patient-side filtration, circuit and exhaust-end control, and ICU room-level airflow engineering with context-appropriate monitoring.Conclusion: Ventilator-exhaust management is feasible with current technologies, but standardized performance indicators and multicenter studies are needed to quantify reductions in cross-infection and occupational exposure and to inform harmonized technical standards and guidance.

> **中文摘要：**
> 有创机械通气（IMV）在重症监护中至关重要，但随呼吸机排气释放的气溶胶仍然是一个未被充分认识的空气传播和职业暴露来源。本综述概述了呼吸机排气产生与在临床工作流程中扩散气溶胶的机制，尤其在气道吸痰、治疗性雾化以及吸入性挥发性镇静过程中会出现增强效应。我们比较了主要的风险缓解策略，包括热湿交换器（HME）装置和高效空气微粒过滤（HEPA）、定向排放以及化学灭活，从有效性、操作复杂度、适应性及证据强度等方面进行分析。在患者—设备—环境框架基础上，我们提出一种基于情景的三级预防策略，将患者端过滤、回路与排气端控制以及重症监护室级别的气流工程与环境适配性监测相结合。结论：利用现有技术可以实现呼吸机排气管理，但仍需标准化的性能指标和多中心研究，以量化交叉感染与职业暴露的降低程度，并为协调的技术标准及指南提供依据。

### 第二部分 AI 大师评价

本文系统梳理了有创机械通气过程中呼吸机排气所引发的气溶胶传播风险与控制策略，旨在揭示其中的潜在职业暴露途径。作者通过总结现有证据，比较多种缓解措施的效果与可行性，并提出了一个以患者、设备和环境为核心的三级防控模型。文章创新地将通气系统排气纳入感染防控体系中，对重症监护室空气传播的再评估具有重要意义。然而，目前缺乏量化标准和多中心验证研究，未来应用与规范制定仍需进一步证据支持。

---

## 5. 重度儿童创伤性脑损伤的分子结构图谱：综合组学揭示潜在治疗通路

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41361486)
**期刊：** Critical care (London, England)
**PMID：** 41361486
**DOI：** 10.1186/s13054-025-05789-7

### 第一部分 原文与翻译

**英文原标题：** The molecular architecture of severe pediatric traumatic brain injury: integrated omics reveal therapeutic pathways.

> **英文摘要：**
> INTRODUCTION: Traumatic brain injury (TBI) remains a leading cause of death and long-term disability in children worldwide. Despite its impact, current clinical management is limited to supportive care, with no FDA-approved therapies to reduce mortality or mitigate lasting neurological consequences. This study presents, to our knowledge, the first integrated multi-omics analysis combining transcriptomic and metabolomic data from pediatric patients with severe TBI spanning both acute and subacute phases offering novel insights into the molecular pathways underlying injury and recovery.
> 
> METHODS: In this prospective, observational cohort study seventeen severe pediatric TBI patients (median age of 13.1 years, median Glasgow Coma Scale (GCS) of 3, and median Injury Severity Score (ISS) of 29) with no pre-existing neurological comorbidities or non-accidental trauma, and corresponding sex and age-matched controls were enrolled between May 2022 and November 2023. The longitudinal bulk transcriptomic analysis of whole blood and metabolomic profiling of serum were performed at three distinct timepoints. The resulting multi-omics datasets were subsequently integrated with validated clinical severity scoring systems to assess changes over a nine-day period of care in the pediatric intensive care unit (PICU).
> 
> RESULTS: We showed that despite the heterogeneity of mechanism and presentation, there was overlap in the transcriptomic and metabolic signatures at each timepoint. There were immediate signs of inflammatory and immune activation, metabolic dysregulation, disturbance of the gut-brain axis in the acute phase. Early markers of T-cell infiltration, such as TRAV35 and ANXA2R, are highly correlated with GCS, and lysophosphatidylcholine 18:0 is highly correlated with NK-cell activation. Multiple gut metabolites, such as indole-3-propionic acid (IPA), and RNA signatures of gut flora are elevated in blood early after TBI. Putrescine elevation at time point one highly correlates with Day 9 red blood cell stimulation. At Day9, multiple lipid species in the metabolome are associated with length of stay and Glasgow Outcome Scale-Extended (GOS-E Peds). By Day 9, both the metabolome and transcriptome show incomplete recovery, marked by highly specific TBI IGH, IGK, and IGL clonal expansion.
> 
> CONCLUSIONS: Despite the heterogeneity in injury mechanisms and clinical presentations, our findings reveal a convergent host response, characterized by shared transcriptomic and metabolic signatures across all time points. This convergence highlights potentially targetable biological pathways and opens the door to the development of novel therapeutic strategies for severe pediatric TBI.

> **中文摘要：**
> 引言：创伤性脑损伤（TBI）仍然是全球儿童死亡和长期残疾的主要原因之一。尽管其影响巨大，目前的临床管理仍局限于支持性治疗，尚无获得FDA批准的疗法能够降低死亡率或减轻持久的神经后遗症。本研究据我们所知首次将重度儿童TBI患者急性期与亚急性期的转录组学与代谢组学数据整合分析，从分子层面提供了损伤与恢复过程的新见解。
> 
> 方法：在这项前瞻性观察性队列研究中，共纳入17例重度儿童TBI患者（中位年龄13.1岁，中位格拉斯哥昏迷评分（GCS）为3，中位损伤严重度评分（ISS）为29），均无既往神经系统合并症或非意外伤，同时入组性别与年龄匹配的对照，研究时间为2022年5月至2023年11月。对外周血进行了三时间点的纵向整体转录组分析，并对血清进行了代谢组学分析。所得多组学数据进一步与经验证的临床病情严重度评分系统整合，用于评估儿童重症监护室（PICU）9天住院期间的动态变化。
> 
> 结果：尽管损伤机制与临床表现存在异质性，各时间点的转录组与代谢特征显示出重叠。急性期表现出显著的炎症与免疫激活、代谢紊乱以及肠脑轴的扰动。早期T细胞浸润标志物（如TRAV35和ANXA2R）与GCS高度相关，溶血磷脂酰胆碱18:0与NK细胞活化高度相关。多种肠源代谢产物（如吲哚-3-丙酸，IPA）及肠道菌群RNA特征在TBI后早期于血液中升高。第一时间点的腐胺升高与第9天红细胞刺激呈高度相关。第9天时，多种脂类代谢物与住院天数及儿童扩展版格拉斯哥预后量表（GOS-E Peds）相关。至第9天，代谢组与转录组均显示恢复不完全，伴随特异性的TBI相关IGH、IGK和IGL克隆扩增。
> 
> 结论：尽管损伤机制和临床表现存在差异，我们的研究揭示了宿主反应的趋同特征，即在所有时间点上均存在共享的转录和代谢标志。这种趋同性提示了可潜在干预的生物学通路，为重度儿童TBI的新型治疗策略开发提供了可能。

### 第二部分 AI 大师评价

本研究通过整合儿童重度TBI患者急性期与亚急性期的转录组及代谢组数据，首次系统揭示了损伤与恢复阶段的分子特征。研究发现，尽管临床表现差异较大，但仍存在共同的代谢与转录学响应，提示炎症调控、免疫活化及肠脑轴紊乱在疾病进程中起重要作用。早期标志物与预后指标的相关性为精准分级评估与疗效预测提供了依据。该研究的创新性在于多组学整合分析揭示潜在治疗靶点，但样本量有限且时间窗口较短，仍需进一步验证。

---

## 6. 基于外周血单细胞免疫特征驱动的小型侵袭性肺结节精准诊断

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41360981)
**期刊：** Nature communications
**PMID：** 41360981
**DOI：** 10.1038/s41467-025-65930-6

### 第一部分 原文与翻译

**英文原标题：** Precise diagnosis of small invasive pulmonary nodules driven by single-cell immune signatures in peripheral blood.

> **英文摘要：**
> Early detection of lung cancer is crucial for improving patient outcomes. However, accurately diagnosing invasive pulmonary nodules and predicting tumor invasiveness remain major clinical challenges. Given the established role of immune dysfunction in cancer development, we hypothesize that peripheral immune profiling could provide a strategy for managing pulmonary nodules. In this multi-center, prospective study, we combine peripheral immune profiling via mass cytometry with machine learning algorithms to develop an integrated pulmonary nodule management platform. This platform accurately distinguishes invasive from non-invasive pulmonary nodules (AUC = 0.952), outperforming established clinical and radiomics-based models. Furthermore, it effectively predicts tumor invasiveness, differentiating minimally invasive from invasive adenocarcinoma (AUC = 0.949), thereby offering valuable guidance for surgical decision-making. In conclusion, the platform demonstrates substantial clinical utility and holds significant promise as a precision tool for future management of pulmonary nodules.

> **中文摘要：**
> 肺癌的早期检测对改善患者预后至关重要。然而，准确诊断侵袭性肺结节并预测肿瘤侵袭性仍是主要的临床难题。鉴于免疫功能障碍在癌症发生中的既定作用，我们假设外周免疫分型可为肺结节的管理提供一种新策略。在本项多中心、前瞻性研究中，我们将通过质谱流式细胞术获得的外周免疫分型与机器学习算法相结合，开发了一套综合性的肺结节管理平台。该平台能够精确区分侵袭性与非侵袭性肺结节（AUC = 0.952），其性能优于现有的临床和基于影像组学的模型。此外，该平台还能有效预测肿瘤的侵袭性，能够区分微浸润性与浸润性腺癌（AUC = 0.949），从而为外科决策提供重要指导。总之，该平台显示出显著的临床应用价值，并在未来肺结节精准管理中具有广阔潜力。

### 第二部分 AI 大师评价

本研究旨在通过外周血单细胞免疫特征构建精准诊断平台，以解决侵袭性肺结节识别的难题。研究采用质谱流式免疫分型结合机器学习，显著提高了结节侵袭性预测的准确性，其AUC值优于传统影像和临床模型。该方法突出了免疫学信号在无创肿瘤评估中的潜力，为外科决策提供量化依据。研究创新性体现在免疫组学与人工智能的整合，但其在大规模真实世界应用中的可推广性仍需进一步验证。

---

## 7. 冷冻保存与液体保存血小板治疗术中出血的比较研究：CLIP-II 随机非劣效性临床试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41360717)
**期刊：** JAMA
**PMID：** 41360717
**DOI：** 10.1001/jama.2025.23355

### 第一部分 原文与翻译

**英文原标题：** Cryopreserved vs Liquid-Stored Platelets for the Treatment of Surgical Bleeding: The CLIP-II Randomized Noninferiority Clinical Trial.

> **英文摘要：**
> IMPORTANCE: Liquid-stored platelets have a shelf-life of 5 to 7 days, limiting availability and resulting in wastage.
> 
> OBJECTIVE: To assess the effectiveness and safety of dimethyl sulfoxide-cryopreserved platelets, which have a shelf-life of 2 years, as a treatment for cardiac surgery bleeding.
> 
> DESIGN, SETTING, AND PARTICIPANTS: The Cryopreserved vs Liquid Platelets II (CLIP-II) trial was a multicenter, randomized, double-blind, parallel-group noninferiority trial, which enrolled patients between August 2021 and April 2024 at 11 Australian tertiary hospitals, with follow-up completed in July 2024. Patients at high risk of platelet transfusion were eligible. Patients were excluded if they had a history of deep vein thrombosis or pulmonary embolism, were coagulopathic, or were females aged 18 to 55 years who were rhesus D (RhD) negative or of unknown RhD status. Of 879 patients meeting inclusion criteria, 182 were excluded and 285 did not consent, leaving 412. Of these, 388 were randomized and 202 received study platelets.
> 
> INTERVENTIONS: Patients received up to 3 units of either group O cryopreserved platelets or conventional liquid-stored platelets, commencing intraoperatively or in the first 24 postoperative hours.
> 
> MAIN OUTCOMES AND MEASURES: The primary outcome was postsurgical chest drain bleeding within the first 24 hours following intensive care unit admission. Noninferiority was defined prospectively as less than 20% greater bleeding in this period. Five secondary and 42 tertiary outcomes were defined a priori.
> 
> RESULTS: Of the 202 transfused patients (mean [SD] age, 64.4 [13] years; 75.7% male), 61 (30.2%) underwent nonelective surgery. The primary outcome did not differ between groups (605 mL in cryopreserved platelet group vs 535 mL in liquid-stored platelet group; ratio of geometric means [cryopreserved to liquid ratio], 1.13 [95% CI, 0.96-1.34]; P = .07). As the confidence interval includes bleeding exceeding the noninferiority margin, noninferiority was not established. Cryopreserved platelet transfusion was associated with higher intraoperative and total perioperative blood loss (ratio of geometric means [cryopreserved to liquid ratio], 1.42 [95% CI, 1.12-1.80]; 1.31 [95% CI, 1.07-1.60], respectively), and increased red cell, plasma, and cryoprecipitate transfusion. While there were no differences in the incidence of prespecified adverse events, patients receiving cryopreserved platelets experienced longer times to extubation and intensive care unit/hospital discharge (median [IQR] duration of ventilation, 25.5 hours [16.1-77.3] vs 23.6 hours [13.1-52.8]; median [IQR] intensive care unit length of stay, 3.8 days [2.0-6.0] vs 3.0 days [1.9-4.9]; median hospital length of stay, 10.9 days [7.87-17.0] vs 9.1 [6.9-14.9]).
> 
> CONCLUSIONS AND RELEVANCE: Cryopreserved platelets did not meet the predefined threshold for noninferiority in hemostatic effectiveness at 24 hours after ICU admission. Additional predefined end points consistently indicated diminished hemostatic effectiveness, although prespecified adverse events were comparable.
> 
> TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03991481.

> **中文摘要：**
> 重要性：液体保存血小板的保存期为 5 至 7 天，限制了可用性并导致浪费。
> 
> 研究目的：评估二甲基亚砜冷冻保存血小板（保存期可达 2 年）在心脏外科出血治疗中的有效性与安全性。
> 
> 研究设计、地点与参与者：冷冻与液体血小板 II（CLIP-II）试验是一项多中心、随机、双盲、平行分组的非劣效性试验，于 2021 年 8 月至 2024 年 4 月在澳大利亚 11 家三级医院开展随访至 2024 年 7 月。符合高风险血小板输注标准的患者有资格入选。若患者有深静脉血栓或肺栓塞病史、凝血功能障碍，或为 18–55 岁的 RhD 阴性或 RhD 状态未知女性，则予以排除。在 879 名符合标准的患者中，182 人被排除，285 人未同意入组，剩余 412 人，其中 388 人被随机分组，202 人接受了研究血小板输注。
> 
> 干预措施：患者在术中或术后 24 小时内接受最多 3 个单位的 O 型冷冻保存血小板或常规液体保存血小板。
> 
> 主要结局与测量：主要终点为重症监护病房入室后 24 小时内的术后胸腔引流出血量。非劣效性预先定义为出血量不超过对照组的 20%。预定义了 5 个次要终点和 42 个三类终点。
> 
> 结果：在 202 名接受输注的患者中（平均[标准差]年龄 64.4 [13] 岁；男性占 75.7%），61 名（30.2%）为非择期手术。主要终点两组无显著差异（冷冻组 605 mL vs 液体组 535 mL；几何均值比 [冷冻/液体] = 1.13 [95% CI, 0.96–1.34]；P = 0.07）。由于置信区间包含超过非劣效性界限的范围，非劣效性未能确立。冷冻血小板输注与更高的术中及围术期总失血量相关（几何均值比依次为 1.42 [95% CI, 1.12–1.80]；1.31 [95% CI, 1.07–1.60]），且需要更多红细胞、血浆及冷沉淀输注。尽管预先设定的不良事件发生率相似，但冷冻血小板组患者拔管和重症监护/出院时间更长（通气中位时间[IQR] 25.5 小时 [16.1–77.3] vs 23.6 小时 [13.1–52.8]；ICU 停留时间 3.8 天 [2.0–6.0] vs 3.0 天 [1.9–4.9]；住院时间 10.9 天 [7.87–17.0] vs 9.1 天 [6.9–14.9]）。
> 
> 结论与意义：冷冻保存血小板在 ICU 入室后 24 小时止血效果方面未达到预设非劣效性标准。进一步的预定义终点显示止血效果一致性下降，但不良事件发生率相当。
> 
> 试验注册：ClinicalTrials.gov 编号 NCT03991481。

### 第二部分 AI 大师评价

该研究通过多中心随机双盲非劣效性试验比较了冷冻保存与液体保存血小板在心外科出血治疗中的止血效果与安全性。结果显示，冷冻血小板未能达到既定非劣效性标准，并与更高的术中及围术期失血量及更长的术后恢复时间相关。尽管安全性类似，但止血有效性略逊一筹。研究为长期储存血小板的可行性与临床应用提供了关键参考，但结果提示其仍需进一步的工艺优化与验证。

---

## 8. 精准免疫治疗以改善脓毒症结局：研究摘要

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41359998)
**期刊：** JAMA
**PMID：** 41359998
**DOI：** 10.1001/jama.2025.24250

### 第一部分 原文与翻译

**英文原标题：** Precision Immunotherapy to Improve Sepsis Outcomes: Research Summary.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该文题旨在探讨应用精准免疫治疗策略来改善脓毒症患者的临床结局，体现出当前免疫调控在重症感染管理中的前沿趋势。尽管摘要缺失，但标题暗示研究可能总结了免疫治疗的靶点、个体化分层与疗效优化方向。该研究有望推动脓毒症从支持性治疗向机制导向的精准干预转变，同时其临床验证与实施可行性仍需进一步研究。

---

## 9. 脓毒症精准治疗：起点的终结？

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41359997)
**期刊：** JAMA
**PMID：** 41359997
**DOI：** 10.1001/jama.2025.24099

### 第一部分 原文与翻译

**英文原标题：** Precision Therapy for Sepsis: The End of the Beginning?

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要可用。

### 第二部分 AI 大师评价

该文章标题暗示了脓毒症精准治疗领域正在经历从探索起步阶段向更成熟实践阶段的转变。虽然目前尚未提供摘要，但可以推测作者可能探讨了精准医疗策略在脓毒症管理中的进展与挑战，反思现有生物标志物、分型方法及个体化干预的科学依据。文章或意在强调临床转化的困难与未来方向，为精准治疗真正改善脓毒症预后铺路。

---

## 10. 精准免疫治疗改善脓毒症结局：ImmunoSep 随机临床试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41359996)
**期刊：** JAMA
**PMID：** 41359996
**DOI：** 10.1001/jama.2025.24175

### 第一部分 原文与翻译

**英文原标题：** Precision Immunotherapy to Improve Sepsis Outcomes: The ImmunoSep Randomized Clinical Trial.

> **英文摘要：**
> IMPORTANCE: Sepsis is heterogeneous, and the optimal strategy for tailoring immunotherapy is uncertain.
> 
> OBJECTIVE: To investigate whether precision immunotherapy guided by the presence of macrophage activation-like syndrome or sepsis-induced immunoparalysis improves organ dysfunction by day 9.
> 
> DESIGN, SETTING, AND PARTICIPANTS: A randomized, double-blind, double-dummy, placebo-controlled clinical trial conducted in 6 countries. Patients with sepsis, defined by Sepsis-3, were included if they had community-acquired or hospital-acquired pneumonia or ventilator-associated pneumonia or bacteremia and sepsis and had displayed either macrophage activation-like syndrome (blood ferritin >4420 ng/mL) or sepsis-induced immunoparalysis (blood ferritin ≤4420 ng/mL and <5000 human leukocyte antigen DR receptors on CD45/CD14 monocytes). The first patient was enrolled August 5, 2021, and the last follow-up, April 29, 2024.
> 
> INTERVENTIONS: Eligible patients were randomized to receive standard care and precision immunotherapy or standard care and placebo. Those in the precision immunotherapy group with macrophage activation-like syndrome received anakinra intravenously (IV) and placebo subcutaneously, and those with sepsis-induced immunoparalysis received subcutaneous recombinant human interferon gamma and IV placebo. Those in the placebo group received both IV and subcutaneous placebo. Treatment was administered for up to 15 days.
> 
> MAIN OUTCOMES AND MEASURES: The primary end point was a decrease of at least 1.4 points in the mean Sequential Organ Failure Assessment (SOFA) score from baseline by day 9. The SOFA score evaluates 6 organ systems, ranging from 0, no dysfunction, to 4, failure, and the total score ranges from 0, normal, to 24, most severe form of multiorgan failure. Key secondary outcomes included 28-day mortality.
> 
> RESULTS: Of 672 patients assessed for eligibility, 281 were randomized and 276 were included in the primary analysis population (mean [SD] age, 70 [13] years; 93 females [33.7%]; median baseline SOFA score, 9 [IQR, 7-11]). The SOFA decrease end point was attained by 46 of 131 patients (35.1%) in the precision immunotherapy group and by 26 of 145 patients (17.9%) in the placebo group (difference, 17.2% [95% CI, 6.8% to 27.2%]; P = .002). Mortality at 28 days was not statistically significantly different between groups. A total of 1069 serious treatment-emergent adverse events (88.8%) were reported; increased incidence of anemia was noted in the anakinra group; and hemorrhage in the recombinant human interferon gamma group.
> 
> CONCLUSIONS AND RELEVANCE: Among patients with sepsis, precision immunotherapy targeting macrophage activation-like syndrome and sepsis-induced immunoparalysis improved organ dysfunction by day 9 compared with placebo.
> 
> TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04990232.

> **中文摘要：**
> 重要性：脓毒症具有异质性，针对性免疫治疗的最佳策略尚不确定。
> 
> 研究目的：探讨依据巨噬细胞活化样综合征或脓毒症诱导的免疫麻痹状态来指导的精准免疫治疗，是否可在第9天改善器官功能障碍。
> 
> 设计、研究地点与参与者：这是一项在6个国家开展的随机、双盲、双模拟、安慰剂对照临床试验。根据Sepsis-3定义诊断为脓毒症的患者被纳入研究，若其患有社区获得性或医院获得性肺炎、呼吸机相关性肺炎或菌血症并合并脓毒症，且出现以下任一情况：巨噬细胞活化样综合征（血清铁蛋白>4420 ng/mL），或脓毒症诱导的免疫麻痹（血清铁蛋白≤4420 ng/mL且CD45/CD14单核细胞上人类白细胞抗原DR受体<5000）。首位患者入组时间为2021年8月5日，最后随访日期为2024年4月29日。
> 
> 干预措施：符合条件的患者被随机分配接受标准治疗加精准免疫治疗，或标准治疗加安慰剂。精准免疫治疗组中巨噬细胞活化样综合征患者静脉给予阿那白滞素并皮下注射安慰剂；脓毒症诱导免疫麻痹者皮下注射重组人干扰素γ并静脉注射安慰剂。安慰剂组患者静脉及皮下注射均为安慰剂。治疗最长可持续15天。
> 
> 主要结局与测量指标：主要终点为第9天平均序贯器官衰竭评估（SOFA）评分相较基线下降至少1.4分。SOFA评分评估6个器官系统，从0（无功能障碍）至4（衰竭），总分为0至24分，代表从无障碍至多器官衰竭最严重水平。次要关键结局包括28日死亡率。
> 
> 结果：在672例评估患者中，281例被随机分组，276例纳入主要分析人群（平均[标准差]年龄70[13]岁；女性93人，占33.7%；基线SOFA中位数9[IQR，7-11]）。SOFA评分下降终点在精准免疫治疗组131例中达46例（35.1%），在安慰剂组145例中为26例（17.9%），差异为17.2%（95%置信区间，6.8%至27.2%；P=.002）。28日死亡率两组间无统计学显著差异。共报告1069例严重治疗相关不良事件（占88.8%）；其中阿那白滞素组贫血发生率增加，重组人干扰素γ组出血发生率升高。
> 
> 结论与意义：在脓毒症患者中，针对巨噬细胞活化样综合征及脓毒症诱导免疫麻痹状态的精准免疫治疗，与安慰剂相比可在第9天改善器官功能障碍。
> 
> 试验注册号：ClinicalTrials.gov编号NCT04990232。

### 第二部分 AI 大师评价

本研究是首个以免疫表型为基础进行精准免疫干预的多国随机对照试验，针对脓毒症的异质性问题提供了实证支持。通过将患者分型为巨噬细胞活化样综合征和免疫麻痹亚型，并分别给予阿那白滞素或干扰素γ，研究发现精准免疫治疗显著改善第9天器官功能。虽然28日死亡率差异未达统计学显著，但结果为免疫分型指导治疗提供了重要依据。研究的创新性在于免疫状态驱动的治疗分层，而局限在于样本量尚需扩大及长期疗效未明。

---

## 11. 镁补充与心动过速性心律失常：一项非随机临床试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41359319)
**期刊：** JAMA internal medicine
**PMID：** 41359319
**DOI：** 10.1001/jamainternmed.2025.6572

### 第一部分 原文与翻译

**英文原标题：** Magnesium Supplementation and Tachyarrhythmias: A Nonrandomized Clinical Trial.

> **英文摘要：**
> IMPORTANCE: Magnesium supplementation is regularly given to acutely ill patients with serum levels below the standard reference range, primarily for the prevention of tachyarrhythmias, such as atrial fibrillation. The evidence for this practice and the specific treatment thresholds used is limited. Conventional observational studies of this question are at risk of confounding by indication and other biases.
> 
> OBJECTIVE: To determine whether giving magnesium supplementation to patients with hypomagnesemia, as defined by a given institution's usual treatment cutoff, reduces adverse clinical outcome using a quasi-experimental study design that plausibly allows for causal inference.
> 
> DESIGN, SETTING, AND PARTICIPANTS: This nonrandomized clinical trial of intensive care unit (ICU) patients undergoing serum magnesium testing was conducted in 93 ICUs across the US and Europe between 2003 and 2022. A fuzzy regression discontinuity design was used, in which individuals just either side of the eligibility cutoff for magnesium supplementation were compared with regard to the study outcomes. This comparison was performed across a range of treatment cutoffs in current use, ranging from 1.6 mg/dL to 2.0 mg/dL. Data were analyzed from August to October 2025.
> 
> EXPOSURES: Magnesium supplementation.
> 
> MAIN OUTCOMES AND MEASURES: The primary outcome was ventricular or supraventricular tachyarrhythmia in the 24 hours after magnesium testing. Secondary outcomes were the occurrence of hypotension or death.
> 
> RESULTS: A total of 478 901 twenty-four-hour treatment windows from 171 727 ICU admissions were included in the study. A total of 72 767 admitted patients (42.4%) were female, 98 960 (57.6%) were male, and the mean (SD) age of the cohort was 63 (16) years. There was no evidence of an effect of magnesium supplementation on the occurrence of tachyarrhythmia, with a risk difference of 0.1% (95% CI, -4.2 to 6.9). This was true across all the cutoff levels evaluated. There was similarly no association with the occurrence of hypotension (risk difference, 1.2%; 95% CI, -0.9 to 17.7) or death (risk difference, 1.4%; 95% CI, -0.6 to 5.3).
> 
> CONCLUSIONS AND RELEVANCE: In this nonrandomized clinical trial, routine supplementation of magnesium with currently used doses and treatment thresholds was not associated with beneficial effects for individuals with serum magnesium values close to those cutoffs.

> **中文摘要：**
> 重要性：镁补充通常用于急性病患者，当其血清镁水平低于标准参考范围时，主要目的是预防心动过速性心律失常，如心房颤动。然而，这种做法的证据以及具体治疗阈值均有限。针对该问题的传统观察性研究容易受到适应症混杂和其他偏倚的影响。
> 
> 目的：通过一种可合理支持因果推断的准实验研究设计，确定根据各机构通常采用的治疗阈值向低镁血症患者给予镁补充，是否能降低不良临床结局。
> 
> 设计、设定与参与者：这项非随机临床试验纳入了在重症监护病房（ICU）接受血清镁检测的患者，研究在2003年至2022年间于美国和欧洲的93家ICU中开展。该研究采用模糊回归不连续设计，将镁补充治疗阈值边缘两侧的个体进行比较，以观察研究结局。比较覆盖当前使用的多种治疗阈值范围，从1.6 mg/dL至2.0 mg/dL。数据分析时间为2025年8月至10月。
> 
> 暴露因素：镁补充。
> 
> 主要结局与测量指标：主要结局为镁检测后24小时内发生室性或室上性心动过速。次要结局为低血压或死亡的发生。
> 
> 结果：研究共纳入171,727例ICU入院病例，共分析478,901个24小时治疗时间窗。其中女性72,767人（42.4%），男性98,960人（57.6%），队列平均（标准差）年龄为63（16）岁。结果显示，镁补充对心动过速性心律失常的发生无显著影响，风险差为0.1%（95% CI，-4.2至6.9）。在所有评估的阈值水平下结果一致。同样，镁补充与低血压（风险差1.2%；95% CI，-0.9至17.7）或死亡（风险差1.4%；95% CI，-0.6至5.3）的发生也无相关性。
> 
> 结论与意义：在这项非随机临床试验中，采用当前常用剂量与治疗阈值进行的常规镁补充，对于接近这些阈值的患者，其血清镁水平并未显示出显著的临床获益。

### 第二部分 AI 大师评价

本研究通过模糊回归不连续设计，利用大样本ICU数据，评估了低镁血症患者常规镁补充的有效性。结果显示，镁补充未能显著减少心动过速性心律失常、低血压或死亡的风险。该研究创新性地将真实世界准实验方法应用于重症患者干预评价，增强了因果推断的可信度。然而，作为非随机试验，其仍可能存在未知混杂因素，对剂量与特定人群的差异效应研究仍需进一步探索。

---

## 12. 28天及以下发热婴儿菌血症和细菌性脑膜炎的预测研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41359314)
**期刊：** JAMA
**PMID：** 41359314
**DOI：** 10.1001/jama.2025.21454

### 第一部分 原文与翻译

**英文原标题：** Prediction of Bacteremia and Bacterial Meningitis Among Febrile Infants Aged 28 Days or Younger.

> **英文摘要：**
> IMPORTANCE: Fever in the first month of life is often the only sign of life-threatening invasive bacterial infection, specifically bacteremia or bacterial meningitis. Most international guidelines recommend routine lumbar punctures for all febrile infants 28 days or younger to rule out bacterial meningitis. Clinical prediction rules may allow for select testing, but limited information exists on their performance to identify infants at low risk for invasive bacterial infections.
> 
> OBJECTIVE: To evaluate the diagnostic accuracy of the updated Pediatric Emergency Care Applied Research Network (PECARN) prediction rule for identifying febrile infants 28 days or younger with bacteremia or bacterial meningitis.
> 
> DESIGN, SETTING, AND PARTICIPANTS: This pooled analysis of 4 published prospective cohort studies from pediatric emergency departments across 6 countries within the global Pediatric Emergency Research Network included previously healthy, non-ill-appearing, full-term (≥37 weeks' gestation) infants aged 28 days or younger with a temperature greater than or equal to 38.0 °C who underwent urine, blood, and serum testing.
> 
> EXPOSURE: Infants were classified as low risk if they had a negative urinalysis/dipstick test result, serum procalcitonin less than or equal to 0.5 ng/mL, and blood absolute neutrophil count less than or equal to 4000/mm3.
> 
> MAIN OUTCOMES AND MEASURES: Meta-analytic methods were applied to assess diagnostic accuracy (sensitivity, specificity, and positive and negative predictive values) of the PECARN rule for detection of infants with invasive bacterial infections (bacteremia or bacterial meningitis).
> 
> RESULTS: Among 1537 infants 28 days or younger (905 male, 1324 hospitalized, 1080 with lumbar punctures), 69 (4.5%) had invasive bacterial infections, including 11 (0.7%) with bacterial meningitis. Overall, 632 (41.1%) met low-risk criteria. The prediction rule had a sensitivity of 94.2% (95% CI, 85.6%-97.8%), specificity of 41.6% (95% CI, 36.7%-46.7%), positive predictive value of 6.9% (95% CI, 4.8%-9.9%), and negative predictive value of 99.4% (95% CI, 98.1%-99.8%) for invasive bacterial infections. In a secondary analysis of 2531 infants from the 2 US-based cohorts from which the rule was originally derived and the 4 validation cohorts, 96 (3.8%) had invasive bacterial infections, 22 (0.9%) had bacterial meningitis, and 1079 (42.6%) were classified as low risk; rule performance was similar. No infants with bacterial meningitis were misclassified in the primary or secondary analyses.
> 
> CONCLUSIONS AND RELEVANCE: The updated PECARN rule had high sensitivity but lower specificity for identifying febrile infants 28 days or younger with invasive bacterial infections in this study, with no missed cases of bacterial meningitis. These results may support shared decision-making regarding select vs routine use of lumbar puncture among infants classified as being at low risk of invasive bacterial infections.

> **中文摘要：**
> 重要性：生命的第一个月内，发热往往是威胁生命的侵袭性细菌感染（尤其是菌血症或细菌性脑膜炎）的唯一表现。多数国际指南建议对所有28天及以下的发热婴儿常规进行腰椎穿刺以排除细菌性脑膜炎。临床预测规则可能允许选择性检测，但目前关于其识别低风险婴儿在侵袭性细菌感染中的表现资料有限。
> 
> 研究目的：评估更新版儿科急诊护理应用研究网络（PECARN）预测规则在识别28天及以下发热婴儿中菌血症或细菌性脑膜炎的诊断准确性。
> 
> 研究设计、地点与参与者：本研究为对全球儿科急诊研究网络中来自6个国家的儿科急诊部门4项已发表的前瞻性队列研究进行的汇总分析。纳入对象为既往健康、外观不病重、足月（胎龄≥37周）、年龄28天及以下、体温≥38.0°C，且接受了尿液、血液及血清检测的婴儿。
> 
> 暴露因素：若婴儿尿液分析/尿试纸检测为阴性，血清降钙素原≤0.5 ng/mL，且血中绝对中性粒细胞计数≤4000/mm³，则被归类为低风险。
> 
> 主要结局与测量指标：采用Meta分析方法评估PECARN规则对侵袭性细菌感染（菌血症或细菌性脑膜炎）检测的诊断准确性（包括敏感性、特异性、阳性预测值及阴性预测值）。
> 
> 结果：在1537名28天及以下的婴儿中（男婴905例，住院1324例，接受腰椎穿刺1080例），共有69例（4.5%）发生侵袭性细菌感染，其中11例（0.7%）为细菌性脑膜炎。总体上，632例（41.1%）符合低风险标准。该预测规则对侵袭性细菌感染的敏感性为94.2%（95% CI，85.6%-97.8%），特异性为41.6%（95% CI，36.7%-46.7%），阳性预测值为6.9%（95% CI，4.8%-9.9%），阴性预测值为99.4%（95% CI，98.1%-99.8%）。在二次分析中（包括美国最初开发该规则的2个队列和4个验证队列，共2531名婴儿），96例（3.8%）患侵袭性细菌感染，22例（0.9%）患细菌性脑膜炎，1079例（42.6%）被归为低风险；预测规则的表现相似。在主要和次要分析中均未出现细菌性脑膜炎被错误分类的病例。
> 
> 结论与意义：在本研究中，更新后的PECARN规则对识别28天及以下发热婴儿侵袭性细菌感染具有较高敏感性但较低特异性，且未遗漏任何细菌性脑膜炎病例。结果支持在被判定为低风险的婴儿中，可基于共同决策方式选择性或常规进行腰椎穿刺操作。

### 第二部分 AI 大师评价

该研究通过整合多国前瞻性队列数据，验证了更新版PECARN规则在识别28天及以下发热婴儿侵袭性细菌感染中的诊断准确性。结果显示该规则具有极高的敏感性和阴性预测值，能够有效识别低风险婴儿，从而减少不必要的腰椎穿刺。其创新点在于基于多中心数据的国际验证，增强了通用性与临床参考价值。然而，其特异性相对较低，提示在临床应用中仍需结合临床判断以避免过度筛查。

---

## 13. 明智选择：比较三种呼吸道取样技术在呼吸机相关肺炎诊断中的碳足迹。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41359067)
**期刊：** Annals of intensive care
**PMID：** 41359067
**DOI：** 10.1186/s13613-025-01597-y

### 第一部分 原文与翻译

**英文原标题：** Choosing wisely: comparing the carbon footprint of three respiratory sampling techniques for ventilator-associated pneumonia.

> **英文摘要：**
> BACKGROUND: Intensive care units (ICU) play a significant role in healthcare global greenhouse gas emissions. Ventilator-associated pneumonia (VAP) is a common ICU-acquired infection, and while microbiological confirmation is essential, the optimal sampling method remains controversial. This study compares the carbon footprint of three diagnostic techniques for VAP-tracheal aspiration (TA), blind bronchial sampling (BBS) and bronchoalveolar lavage (BAL) using single-use bronchoscopes-while also assessing their economic cost and professional impact to support more sustainable decision-making in the ICU.
> 
> METHODS: The carbon footprint of each technique was estimated using a simplified Life Cycle Assessment (LCA) methodology via the "Carebone©" tool. Emission factors for drugs and devices were calculated. The economic costs of each procedure were also assessed. Finally, a survey of nursing staff was conducted to assess the professional impact of these techniques.
> 
> RESULTS: Tracheal aspiration had the lowest emissions (0.57 kgCOe) and cost (€4), followed by BBS (2.82 kgCOe, €24) and BAL (6.60 kgCOe, €209). Nursing staff perceived BBS the most practical technique overall, and BAL the most technically demanding. In 2023, 341 procedures were performed in our ICU (73% BBS, 21% BAL, 6% TA), generating 1,181 kgCO2e and costing €20,835. Adopting TA exclusively in our ICU would reduce emissions by 84% and costs by 93%, whereas using BAL exclusively would increase emissions by 91% and costs by 242%.
> 
> CONCLUSION: Bronchoalveolar lavage was associated with the highest carbon footprint and cost. These findings can help clinicians choose more sustainable methods for microbiological confirmation of VAP.

> **中文摘要：**
> 背景：重症监护病房（ICU）在医疗体系的全球温室气体排放中占有重要比例。呼吸机相关肺炎（VAP）是ICU常见的院内感染，尽管进行微生物学确诊至关重要，但最佳取样方法仍存在争议。本研究比较了三种用于VAP诊断的技术——气管吸取（TA）、盲法支气管取样（BBS）和使用一次性支气管镜的支气管肺泡灌洗（BAL）——在碳足迹方面的差异，同时评估其经济成本与对医护人员的影响，以支持ICU中更具可持续性的决策。
> 
> 方法：采用“Carebone©”工具利用简化的生命周期评估（LCA）方法估算每种技术的碳足迹，并计算所用药品与器械的排放因子。同时评估每种操作的经济成本。最后，通过护理人员问卷调查分析这些技术对专业实践的影响。
> 
> 结果：气管吸取的排放量最低（0.57 kgCOe），成本为4欧元，其次为BBS（2.82 kgCOe，24欧元）和BAL（6.60 kgCOe，209欧元）。护理人员认为BBS整体上是最实用的技术，而BAL最具技术挑战性。2023年本ICU共实施341次相关操作（73%为BBS，21%为BAL，6%为TA），产生1,181 kgCO2e排放，总成本20,835欧元。若ICU仅采用TA，可减少84%的排放并节约93%的成本；若仅使用BAL，则排放增加91%，成本上升242%。
> 
> 结论：支气管肺泡灌洗的碳足迹与成本最高。研究结果有助于临床医生在VAP微生物学确证过程中选择更具环境可持续性的取样方法。

### 第二部分 AI 大师评价

本研究聚焦于重症监护环境中的碳减排问题，首次系统比较了三种呼吸机相关肺炎诊断取样方法的碳足迹与经济成本。研究利用简化生命周期评估方法量化排放，并结合护理人员反馈评估可行性与专业影响。结果显示气管吸取在碳排放与成本方面最具优势，而BAL的负担最高。该研究的创新之处在于将环境可持续性引入ICU感染诊断决策，但其局限在于样本量较小及模型估算的精度依赖。总体而言，该工作为未来低碳医疗实践提供了实证依据。

---

## 14. 脓毒性休克的当前标准治疗

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41359028)
**期刊：** Intensive care medicine
**PMID：** 41359028
**DOI：** 10.1007/s00134-025-08211-6

### 第一部分 原文与翻译

**英文原标题：** Current standard of care for septic shock.

> **英文摘要：**
> Sepsis is a syndrome of life-threatening organ dysfunction that results from dysregulated host response to infection, with septic shock defined as persistent hypotension despite fluid resuscitation, a serum lactate > 2 mmol/L and the need for a vasopressor infusion to maintain a mean arterial pressure of at least 65 mmHg. Approximately, 49 million cases of sepsis are recorded worldwide annually, with 11 million sepsis-related deaths, the majority occurring in patients with septic shock. A substantial proportion of survivors suffer from moderate to severe functional limitations including physical, cognitive and psychological disability, exacerbation of pre-existing chronic conditions and a high incidence of re-hospitalisation in the first 12 months after the initial diagnosis. Optimal management of patients with septic shock requires prompt and reliable recognition of patients with sepsis who require additional haemodynamic support. Initially, patients will need judicious intravenous fluids and consideration of the need for vasopressors such as norepinephrine. Administration of appropriate antibiotics and consideration for control of the source of infection are also required. In the optimisation phase, depending on patients' comorbidities and response to therapy, the balance of fluid therapy, vasopressors and potentially the addition of an inotropic agent will need to be adjusted, based on clinical findings and haemodynamic and biochemical parameters. For those patients who do not respond to initial therapy, more intensive monitoring may be required with consideration of adjunctive therapies such as corticosteroids, vasopressin, angiotensin II or other rescue therapies to achieve cardiovascular stability. Once stability has been achieved, clinicians need to consider strategies to ameliorate the potential long-term effects on survivors, while keeping in mind the perspective and experience of their patients.

> **中文摘要：**
> 脓毒症是一种由宿主对感染的失调反应引起的、危及生命的器官功能障碍综合征。脓毒性休克被定义为在液体复苏后仍存在持续性低血压、血清乳酸＞2 mmol/L，并需要输注血管加压药以维持平均动脉压至少65 mmHg。全球每年约报告4900万例脓毒症病例，其中约有1100万人因脓毒症死亡，大多数发生于脓毒性休克患者中。相当比例的幸存者存在中度至重度功能受限，包括身体、认知及心理障碍，既往慢性疾病的加重，以及在初次诊断后12个月内再入院率较高。对脓毒性休克患者的最佳管理需要及时且可靠地识别出那些需要额外血流动力学支持的脓毒症患者。初始阶段，患者需要谨慎给予静脉输液，并评估是否需要使用去甲肾上腺素等血管加压药。同时，应及时给予适当抗生素，并考虑感染源控制。在治疗优化阶段，应根据患者的合并症和治疗反应，基于临床表现以及血流动力学和生化参数，调整液体治疗、血管加压药，以及必要时添加正性肌力药物。对于对初始治疗无反应的患者，可能需要更密集的监测，并考虑使用肾上腺糖皮质激素、加压素、血管紧张素II或其他救援疗法以实现心血管稳定。一旦患者病情稳定，临床医生需制定策略以减轻存活者潜在的长期后遗影响，同时关注患者的感受与体验。

### 第二部分 AI 大师评价

本文综述了脓毒性休克的定义、流行病学及管理的最新标准。作者强调早期识别和及时干预的重要性，包括液体复苏、血管加压药物、抗菌治疗及感染源控制。文章详细阐述了不同治疗阶段中血流动力学支持的动态调整及对顽固性休克的辅助治疗选择。其创新在于系统整合了多重治疗策略与长期管理思路，但未涉及新型干预的循证支持，是一篇面向临床实践的权威性综述。

---

## 15. 虚弱：是心脏骤停结局的预后标志还是自我实现的预言？

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41359027)
**期刊：** Intensive care medicine
**PMID：** 41359027
**DOI：** 10.1007/s00134-025-08239-8

### 第一部分 原文与翻译

**英文原标题：** Frailty: a prognostic marker or a self-fulfilling prophecy in cardiac arrest outcomes?

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该论文探讨了虚弱（frailty）在心脏骤停预后评估中的作用，聚焦于其是否仅反映患者整体生理储备的客观状态，或在临床决策中被过度强调，导致潜在的自我实现预言效应。尽管尚无摘要，但题目暗示作者可能讨论虚弱与复苏结果之间的复杂因果关系。研究意义在于呼吁对老年或虚弱患者进行更公平、循证的急救决策，避免主观偏差。局限性在于若缺乏实证数据，结论可能主要停留在概念层面。

---

## 16. 在美国获得 H-1B 签证资助的医疗卫生专业人员

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41160415)
**期刊：** JAMA
**PMID：** 41160415
**DOI：** 10.1001/jama.2025.20931

### 第一部分 原文与翻译

**英文原标题：** Health Care Professionals Sponsored for H-1B Visas in the US.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

该研究关注在美国获得 H-1B 签证资助的医疗卫生专业人员，聚焦移民政策与医疗人力资源之间的关系。尽管无摘要，但标题提示其可能分析签证制度对医疗系统的劳动力构成影响。该主题具有现实政策意义，尤其在医务人力短缺与国际人才流动加剧的背景下。研究的创新性可能在于量化签证资助规模与专业分布，但论文的局限在于公开信息匮乏无法评估研究方法与结论。

---

## 17. 针对早期脓毒性休克毛细血管再充盈时间的个体化血流动力学复苏：ANDROMEDA-SHOCK-2 随机临床试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41159835)
**期刊：** JAMA
**PMID：** 41159835
**DOI：** 10.1001/jama.2025.20402

### 第一部分 原文与翻译

**英文原标题：** Personalized Hemodynamic Resuscitation Targeting Capillary Refill Time in Early Septic Shock: The ANDROMEDA-SHOCK-2 Randomized Clinical Trial.

> **英文摘要：**
> IMPORTANCE: The optimal strategy for hemodynamic resuscitation in early septic shock remains uncertain.
> 
> OBJECTIVE: To determine the effect of a personalized hemodynamic resuscitation protocol targeting capillary refill time (CRT-PHR) on a hierarchical composite outcome of mortality, duration of vital support, and length of hospital stay.
> 
> DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial was conducted in 86 centers in 19 countries. Patients within the first 4 hours of septic shock were included between March 2022 and April 2025, with last follow-up in July 2025.
> 
> INTERVENTIONS: Patients were randomized to undergo CRT-PHR (n = 720), including assessment of pulse pressure, diastolic arterial pressure, fluid responsiveness, and bedside echocardiography, to tailor fluids, vasopressors, and inotropes, vs usual care (n = 747).
> 
> MAIN OUTCOMES AND MEASURES: The primary outcome was a hierarchical composite of mortality, duration of vital support (vasoactives, mechanical ventilation, and kidney replacement therapy), and length of hospital stay assessed at 28 days. A win ratio was calculated for the primary outcome by comparing all possible patient pairs, starting with the first event in the hierarchy and stratified by median APACHE (Acute Physiology and Chronic Health Evaluation) II score at admission. Secondary outcomes were mortality, vital support-free days, and length of hospital stay at 28 days.
> 
> RESULTS: From 1501 randomized patients, 1467 were included in the primary analysis (mean age, 66 [17] years; 43.3% female). There were 131 131 wins (48.9%) in the CRT-PHR group vs 112 787 (42.1%) in the usual care group for the hierarchical composite primary outcome, with a win ratio of 1.16 (95% CI, 1.02-1.33; P = .04). Individual wins for death were 19.1% vs 17.8%; duration of vital support, 26.4% vs 21.1%; and length of hospital stay, 3.4% vs 3.2% in the intervention vs usual care groups, respectively.
> 
> CONCLUSIONS AND RELEVANCE: Among patients with early septic shock, a personalized hemodynamic resuscitation protocol targeting capillary refill time was superior to usual care for the primary composite outcome, primarily due to a lower duration of vital support.
> 
> TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05057611.

> **中文摘要：**
> 重要性：早期脓毒性休克的最佳血流动力学复苏策略仍不确定。
> 
> 目的：评估一种以毛细血管再充盈时间（CRT-PHR）为目标的个体化血流动力学复苏方案对分层复合结局（包括死亡率、生命支持持续时间和住院时间）的影响。
> 
> 设计、地点与参与者：这项随机临床试验在19个国家的86个中心开展。纳入在脓毒性休克发作后4小时内的患者，入组时间为2022年3月至2025年4月，最后随访时间为2025年7月。
> 
> 干预措施：患者被随机分配接受CRT-PHR干预（n=720），该方案包括评估脉压、舒张动脉压、液体反应性及床旁超声心动图，以便个体化调整补液、血管活性药物及正性肌力药物；对照组为常规治疗（n=747）。
> 
> 主要结局与测量指标：主要结局为28天内死亡率、生命支持持续时间（包括血管活性药物、机械通气及肾脏替代治疗）和住院时间的分层复合指标。通过比较所有可能的患者配对并按入院时中位APACHE II评分分层，计算主要结局的胜利比（win ratio）。次要结局包括28天时的死亡率、无生命支持生存天数和住院时间。
> 
> 结果：在1501名随机入组患者中，1467名被纳入主要分析（平均年龄66［17］岁，女性占43.3%）。在分层复合主要结局中，CRT-PHR组获得131,131次胜利（48.9%），而常规治疗组为112,787次（42.1%），胜利比为1.16（95%置信区间1.02–1.33，P=0.04）。在具体事件中，死亡的胜利比例为19.1%对17.8%，生命支持持续时间为26.4%对21.1%，住院时间为3.4%对3.2%（分别对应干预组与对照组）。
> 
> 结论与意义：在早期脓毒性休克患者中，以毛细血管再充盈时间为目标的个体化血流动力学复苏方案在主要复合结局上优于常规治疗，这主要归因于生命支持持续时间的减少。
> 
> 试验注册：ClinicalTrials.gov编号：NCT05057611。

### 第二部分 AI 大师评价

本研究通过ANDROMEDA-SHOCK-2多中心随机临床试验，验证了以毛细血管再充盈时间为目标的个体化血流动力学复苏在早期脓毒性休克中的效果。结果显示，该策略在主要复合结局上优于常规治疗，尤其体现在缩短生命支持时间方面。研究创新性地将床旁生理指标应用于个体化复苏决策，提示精准复苏的潜力。然而，研究的复杂性和各中心执行差异可能影响推广性，仍需进一步验证其在不同人群及资源环境中的适用性。

---

## 18. 重度代谢性酸中毒合并急性肾损伤的碳酸氢钠治疗：BICARICU-2 随机临床试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41159812)
**期刊：** JAMA
**PMID：** 41159812
**DOI：** 10.1001/jama.2025.20231

### 第一部分 原文与翻译

**英文原标题：** Sodium Bicarbonate for Severe Metabolic Acidemia and Acute Kidney Injury: The BICARICU-2 Randomized Clinical Trial.

> **英文摘要：**
> IMPORTANCE: The effect of sodium bicarbonate infusion on outcome in patients with severe metabolic acidemia and moderate to severe acute kidney injury is unknown.
> 
> OBJECTIVE: To determine whether sodium bicarbonate infusion is associated with day 90 all-cause mortality in patients with severe metabolic acidemia and moderate to severe acute kidney injury.
> 
> DESIGN, SETTING, AND PARTICIPANTS: Randomized, open-label, clinical trial conducted with 640 patients in 43 French intensive care units from October 6, 2019, to December 19, 2023, with 90-day follow-up. The last date of follow-up was June 17, 2024. Adults with severe metabolic acidemia (defined as pH ≤7.20) and moderate to severe acute kidney injury were enrolled.
> 
> INTERVENTION: Patients were randomized 1:1 to receive either intravenous sodium bicarbonate infusion or no sodium bicarbonate to target an arterial pH of 7.30 or higher.
> 
> MAIN OUTCOMES AND MEASURES: The primary outcome was day 90 all-cause mortality. Secondary outcomes included day 28 and day 180 all-cause mortality; use of organ support therapy, vasopressors, or invasive mechanical ventilation; intensive care unit and hospital length of stay; intensive care unit-acquired infections; fluid balance; day-7 Sequential [Sepsis-related] Organ Failure Assessment score (6 organ systems' function is evaluated and scored from 0 [no dysfunction] to 4 [failure]; total score ranges from 0 [normal] to 24 [maximum failure]); and major adverse kidney events on day 90.
> 
> RESULTS: Among 640 randomly assigned patients, 627 were analyzed (313 in the control group and 314 in the bicarbonate group). The median age was 67 years (IQR, 59-74 years); 194 of 314 patients (62%) in the bicarbonate group and 185 of 313 controls (59%) were male. In the primary analysis, day 90 all-cause mortality was 195 of 314 patients (62.1%) in the bicarbonate group and 193 of 313 (61.7%) in the control group (absolute difference, 0.4; 95% CI, -7.2 to 8.0; P = .91). There was no evidence of a group effect on day 28 or day 180 all-cause mortality. Among 18 secondary outcomes, kidney replacement therapy was used in 109 of 314 (35%) bicarbonate group patients and 157 of 313 (50%) controls (absolute difference, -15.5; 95% CI, -23.1 to -7.8). No evidence of a group effect was found on other secondary outcomes, including adverse events.
> 
> CONCLUSIONS AND RELEVANCE: For patients with severe metabolic acidemia and moderate to severe acute kidney injury, intravenous sodium bicarbonate did not affect mortality.
> 
> TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04010630.

> **中文摘要：**
> 重要性：碳酸氢钠输注对重度代谢性酸中毒并中度至重度急性肾损伤患者预后的影响尚不清楚。
> 
> 目的：确定碳酸氢钠输注是否与重度代谢性酸中毒并中度至重度急性肾损伤患者的90天全因死亡率相关。
> 
> 设计、场所与参与者：这是一项随机、开放标签的临床试验，于2019年10月6日至2023年12月19日期间在法国43家重症监护病房中进行，共纳入640例患者，并进行90天随访。最后一次随访日期为2024年6月17日。研究入选对象为患有重度代谢性酸中毒（定义为pH ≤7.20）且伴有中度至重度急性肾损伤的成年患者。
> 
> 干预措施：患者按1:1比例随机分配，分别接受静脉碳酸氢钠输注或不予碳酸氢钠治疗，以达到动脉pH≥7.30的目标。
> 
> 主要结局与测量指标：主要结局为第90天全因死亡率。次要结局包括第28天及第180天全因死亡率；器官支持治疗、血管加压药或有创机械通气的使用情况；重症监护病房与医院的住院时长；重症监护病房获得性感染；液体平衡；第7天序贯（与脓毒症相关）器官衰竭评估（SOFA）评分（6个器官系统的功能被评估并分别评分0[无功能障碍]至4[衰竭]，总分0[正常]至24[完全衰竭]）；以及第90天主要不良肾脏事件。
> 
> 结果：在640名随机分配的患者中，共分析627例（对照组313例，碳酸氢钠组314例）。中位年龄67岁（IQR，59–74岁）；碳酸氢钠组中194例患者（62%）为男性，对照组中185例（59%）为男性。在主要分析中，第90天全因死亡率在碳酸氢钠组为195/314（62.1%），对照组为193/313（61.7%）（绝对差0.4；95% CI，-7.2至8.0；P = .91）。在第28天或第180天全因死亡率方面未发现组间差异的证据。在18项次要结局中，肾脏替代治疗的使用率分别为碳酸氢钠组109/314（35%）和对照组157/313（50%）（绝对差 -15.5；95% CI，-23.1至 -7.8）。除此之外，在其他次要结局（包括不良事件）上未发现组间差异。
> 
> 结论与意义：对于重度代谢性酸中毒并中度至重度急性肾损伤患者，静脉碳酸氢钠输注并未影响死亡率。
> 
> 试验注册号：ClinicalTrials.gov 标识码 NCT04010630。

### 第二部分 AI 大师评价

本研究BICARICU-2随机临床试验旨在评估静脉碳酸氢钠输注对重度代谢性酸中毒并急性肾损伤患者死亡率的影响。研究在法国43家ICU中招募640名患者，结果显示碳酸氢钠治疗在90天、28天及180天全因死亡率方面均无显著差异。然而，该治疗显著减少了肾脏替代治疗的使用率，提示其或具潜在肾保护作用。总体而言，本研究以高水平随机设计提供了重要的临床证据，但其开放标签设计及特定人群限制了外推性。

---

速递结束，祝您工作愉快！